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1392Objective: This study examined the impact of neoadjuvant chemotherapy and concurrent high-dose radiation
therapy on survival in patients with node-negative T3 and T4 non–small cell lung cancer.
Methods: A total of 110 consecutive patients underwent surgical resection for invasive T3N0M0 (94 patients)
and T4N0M0 (16 patients) non–small cell lung cancer between 1979 and 2008. Forty-seven patients received
neoadjuvant chemotherapy and concurrent high-dose (5940 cGy) radiation therapy before resection (Chemo-
RT group). Sixty-three patients underwent surgical resection without receiving induction chemoradiotherapy
(Surg group), of whom 21 received neoadjuvant radiation, 19 received adjuvant radiation, 17 received surgery
alone, 2 received adjuvant chemotherapy, 2 received adjuvant chemoradiotherapy, and 2 received brachytherapy.
Survival of the Chemo-RT and Surg groups was compared using both crude and adjusted Cox proportional
hazards models.
Results: The 5-year, 10-year, andmedian survivals were 61%, 50%, and 90months, respectively, in the Chemo-
RT group versus 22%, 14%, and 22 months, respectively, in the Surg group. Subjects in the Surg group had an
increased risk of death (hazard ratio, 2.60; 95% confidence interval, 1.62–4.18; P ¼ .0001) compared with the
Chemo-RT group. After adjustment for potential confounding variables of age, sex, tumor size, tumor location,
type of operation, and decade of care, subjects in the Surg group remained at increased risk of death (hazard
ratio, 2.81; 95% confidence interval, 1.45–5.44, P ¼ .002) compared with the Chemo-RT group.
Conclusions: Aggressive treatment of node-negative invasive T3 and T4 NSCLC with induction chemoradio-
therapy may significantly prolong survival. This approach should be evaluated in a prospective multicenter
national trial. (J Thorac Cardiovasc Surg 2011;141:1392-7)The lung cancer staging system outlines the T3 and T4
tumor descriptor as a diverse group of locally advanced
tumors. In general, T3 tumors are resectable, and T4 tumors
are generally unresectable because of their invasion into
adjacent organs or major vessels. T3 and T4 tumors may
be central or peripheral. Peripheral T3 tumors may involve
the parietal pleura, chest wall, diaphragm, or superior
sulcus. Central T3 tumors invade the mediastinal pleura
or fat, or may involve the pericardium or central bronchus
within 2 cm of the carina. Peripheral T4 tumors invade
the vessels in the superior sulcus or the vertebral body,
and central T4 tumors invade the left atrium, aorta, or intra-
pericardial portion of the main pulmonary arteries, or
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The Journal of Thoracic and Cardiovascular SurUnfortunately, many of these T3 and T4 lung cancers
have associated lymph node involvement. When N2 disease
is present, survival is poor and resection is generally contra-
indicated.1,2 Likewise, incomplete resection has been
associated with a dismal prognosis.3 Our favorable results
with induction-concurrent chemoradiotherapy in patients
with N2 disease have led us to use this approach in many
node-negative patients with T3 and T4 tumors to increase
the likelihood of an R0 resection and treat unsuspected
micro-metastatic nodal or systemic disease.4
This report presents our results in these patients with
node-negative locally advanced tumors, comparing treat-
ment outcomes in patients who received induction chemo-
radiotherapy (Chemo-RT) with those who did not (Surg).MATERIALS AND METHODS
Since 1979, we have maintained a prospective database on all patients
undergoing resection for lung cancer. Patient tracking is ongoing, and no
patient has been lost to follow-up. Patients undergoing resection between
August 1979 and April 2008 were evaluated, and those with predominantly
bronchioalveolar cell lung cancers were excluded.
In 2009, the International Association for the Study of Lung Cancer up-
graded T2 tumors greater than 7 cm in diameter to T3 and downgraded T4
tumors characterized by intralobar satellite nodules to T3.5 These changes
updated the Fifth Edition of the American Joint Committee on Cancer
(AJCC) Cancer Staging Manual (1997).6 We used the Fifth Edition in
this report because our patients were prospectively staged. However,gery c June 2011
Abbreviations and Acronyms
CI ¼ confidence interval
CT ¼ computed tomography
FEV1 ¼ forced expiratory volume in 1 second
HR ¼ hazard ratio
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
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excluded because those tumors are generally not invasive (although they in-
dicate a poorer prognosis). Patients with invasive tumors were treated as
having stage III non–small cell lung cancer (NSCLC) according to the pro-
tocol at the time.
All patients had a complete history and physical, and a chest computed
tomography (CT) scan. Since 2000, patients with suspected lung cancer
have undergone a positron emission tomography (PET) scan. All patients
had complete pulmonary function testing, and most of those aged more
than 50 years had a cardiac stress test. Brain CT or magnetic resonance
imaging was performed preoperatively to exclude brain metastases. In pa-
tients receiving induction therapy, the T status was determined by history
and CT. Patients without direct evidence of chest wall invasion, who had
tumor abutting the chest wall and pain localized to that area, were consid-
ered to have T3 tumors. In patients receiving no induction therapy, the
T status was determined by pathology. All patients had staging of the
mediastinal lymph nodes by CT and invasive staging when enlarged or
PET-positive lymph nodes were identified in the mediastinum. However,
routine invasive staging for all patients with T3 or T4 tumors was not car-
ried out early in this series. Tumors located in the inner third of the lung
field, as visualized on CT, and those visualized by bronchoscopy were con-
sidered to be central tumors. No distinction was made between peripheral
lung cancers invading the chest wall and superior sulcus tumors. These
tumors were classified according to their T descriptor. Tumor size was de-
termined by pathology in patients who received no induction therapy and
by CT in patients who received neoadjuvant therapy. All operations were
performed by thoracotomy. Patients receiving concurrent high-dose radia-
tion and chemotherapy were managed by a strict protocol postoperatively,
as reported previously.4 In patients with peripheral tumors, an extrapleural
resection without chest wall resection was carried out if the pleura easily
stripped from the chest wall. If there was any adherence, an en bloc chest
wall resection was performed.
The 2 groups of patients (Chemo-RT vs Surg) were compared using
clinical and demographic characteristics (Table 1). Continuous variables
were compared using the Student t test or Wilcoxon rank-sum tests. Cate-
goric variables were compared with Fisher’s exact test; chi-square testing
was used for analyses of variables with more than 2 categories. Compari-
sons of survival were made with Cox proportional hazards models. The
proportional hazards assumption was met. To control for potential con-
founding variables of the association between neoadjuvant chemoradio-
therapy and survival, an a priori model was used, with age, sex, forced
expiratory volume in 1 second (FEV1), tumor size, tumor location (central
vs peripheral), operation type (total pneumonectomy vs lesser resection),
and decade of care entered into the model with neoadjuvant chemoradio-
therapy status. In addition, we performed a propensity score-adjusted re-
gression analysis, with propensity scores for receipt of chemotherapy
calculated from logistic regression models, including all measured covari-
ates as predictors of chemotherapy status. Kaplan–Meier curves with log-
rank testing demonstrated unadjusted differences in survival between the 2
treatment categories. All statistical analyses, with the exception of the gen-
eration of Kaplan–Meier survival curves (SPSS v 17; SPSS Inc, Chicago,
IL), were carried out with SAS v 9.1 software (SAS Institute Inc, Cary,The Journal of Thoracic and CarNC). This study was approved by the Boston University Internal Review
Board.RESULTS
A total of 110 patients (94 with T3 and 16 with T4 node-
negative NSCLC) underwent resection. Forty-seven pa-
tients received induction chemoradiotherapy (Chemo-RT
group) consisting of external beam radiotherapy (5940
cGy) and concurrent chemotherapy. Thirty-eight patients
received a cisplatinum doublet, 8 patients received a carbo-
platinum doublet, and 1 patient with a kidney transplant
received paclitaxel alone. Thirty-eight of these patients
(77%) underwent mediastinoscopy before induction
therapy.
Sixty-three patients underwent surgical resection without
induction chemoradiotherapy (Surg group). Seventeen
patients underwent surgery alone, 21 patients underwent in-
duction radiotherapy, 19 patients underwent adjuvant radio-
therapy, 2 patients underwent intraoperative brachytherapy,
2 patients underwent adjuvant chemotherapy, and 2 patients
underwent adjuvant chemoradiotherapy (Table 2). Twenty-
four of these patients underwent mediastinoscopy (38%),
and 2 of these patients underwent Chamberlain procedures.
The type of resection performed in both groups is shown in
Table 2. A sublobar resection was performed only when
pulmonary function or performance status was compro-
mised.
The disease pattern responsible for each T descriptor
assignment is shown in Table 3. When compared with the
Surg group, a higher percentage of patients in the Chemo-
RT group had chest wall or mediastinal fat invasion as
opposed to parietal pleura involvement, which accounted
for their T3 assignment.
Table 1 demonstrates the clinical and demographic char-
acteristics of the study population. Subjects who received
neoadjuvant chemotherapy had a higher FEV1 (2.37 
0.78 L vs 2.00  0.67 L, P ¼ .02) and were more likely
to have had more recent care (in the 1990s and 2000s, rather
than the 1980s, P ¼ .001).
In the unadjusted model, subjects who did not receive
neoadjuvant chemotherapy had an increased risk of death
(hazard ratio [HR], 2.60; 95% confidence interval [CI],
1.62–4.18; P ¼ .0001) compared with subjects who had
neoadjuvant chemotherapy. The 5-year, 10-year, and
median survivals were 61%, 50%, and 90 months, respec-
tively, in the Chemo-RT group versus 22%, 14%, and 22
months, respectively, in the Surg group.
After adjustment for a priori-defined potential confound-
ing variables of age, FEV1, T descriptor, tumor size, sex,
central or peripheral location of tumor, operation type,
and decade of care, subjects in the Surg group alone re-
mained at increased risk of death (HR, 2.81; 95% CI,
1.45–5.44; P ¼ .002; Figure 1, A) compared with subjects
who had neoadjuvant chemotherapy. Results were similardiovascular Surgery c Volume 141, Number 6 1393
TABLE 1. Clinical and demographic subject characteristics
Variable mean
(SD) or N (%)
Total
N ¼ 110, unless
otherwise
specified
Chemo-RT
N ¼ 47
Surg
N ¼ 63 P
Age, y 62.3  9.7 60.5  10.4 63.7  9.0 .09
Sex ¼ male 75 (68%) 26 (55.3%) 46 (73.0%) .07
T descriptor ¼ 3 91 (82.7%) 36 (76.6%) 55 (83.7%) .20
Tumor size, cm;
N ¼ 108
5.31  2.6 5.54  2.4 5.16  2.7 .27
Central tumor 42 (38.2%) 22 (46.8%) 20 (31.8%) .12
FEV1, L 2.15  0.74 2.37  0.78 2.0  0.67 .02y
Pneumonectomyz 22 (20%) 12 (26%) 10 (17%) .24
Complete pathologic
response; N ¼ 71
30 (43.5%) 21 (45.7%) 9 (39.1%)* .80
Cell type: .78
Squamous 42 (38.2%) 17 (36.2%) 25 (39.7%)
Adenocarcinoma 32 (29.1%) 13 (27.7%) 19 (30.2%)
Adenosquamous 8 (7.3%) 4 (8.5%) 4 (6.3%)
Non–small cell
(NOS)
28 (25.5%) 13 (27.7%) 15 (23.8%)
Decade of care .001y
1980s 45 (40.9%) 1 (2.13%) 44 (69.8%)
1990s 36 (32.7%) 23 (48.9%) 13 (20.6%)
2000s 29 (26.4%) 23 (48.9%) 6 (5.5%)
FEV1, Forced expiratory volume in 1 second; NOS, not otherwise specified; SD, stan-
dard deviation. *Twenty-one patients received induction external radiation therapy.
yStatistically significant P value. zRemaining patients underwent the operations listed
in Table 2.
TABLE 3. Factor responsible for the T descriptor
T3 tumors
Chemo-RT group Surg group
Parietal pleura N ¼ 8;
21%
N ¼ 30;
53%
Chest wall N ¼ 16;
42%
N ¼ 19
34%
Mediastinal fat N ¼ 10;
26%
N ¼ 4;
7%
Diaphragm N ¼ 1;
3%
N ¼ 1;
2%
<2 cm carina N ¼ 3;
8%
N ¼ 2;
4%
Total N ¼ 38;
100%
N ¼ 56;
100%
T4 tumors
Chemo-RT group Surg group
PA/atrium N ¼ 7;
78%
N ¼ 7;
100%
Vertebral body N ¼ 1;
11%
N ¼ 0;
0%
Subclavian artery N ¼ 1;
11%
N ¼ 0;
0%
Total N ¼ 9;
100%
N ¼ 7;
100%
PA, Pulmonary artery.
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1.33–4.4; P ¼ .006).
In addition to the absence of neoadjuvant chemoradio-
therapy, significant univariate predictors of mortality were
age (HR per year, 1.058; 95% CI, 1.03–1.08; P ¼ .0001),
FEV1 (HR per liter, 0.552; 95% CI, 0.41–0.75;
P ¼ .0001), and decade of care (HR 0.70 with each in-
creased decade of care; 95% CI, 0.52–0.93; P ¼ .015). In-
cluding these variables in 1 model demonstrated that the
only independent predictors of increased mortality were
older patients (HR, 1.06; 95% CI, 1.03–1.09; P ¼ .0004)
and absence of neoadjuvant chemotherapy (HR, 2.34;
95% CI, 1.27–4.31; P ¼ .007). In the Chemo-RT group,
the tumor location, type of resection, presence or absence
of residual tumor (data not available for 1 patient), and
T status did not affect survival.TABLE 2. Type of resection
Type Chemo-RT N Chemo-RT% Surg N Surg%
Pneumonectomy 12 25% 10 16%
Bilobectomy 4 9% 3 5%
Lobectomy 26 55% 43 68%
Segmental resection 1 2% 1 2%
Wedge resection 4 9% 6 9%
Total 47 100% 63 100%
1394 The Journal of Thoracic and Cardiovascular SurMedian survival was greatest for those who received
surgical resection and neoadjuvant chemoradiotherapy
(90 months; 95% CI, 46; no estimate is available), com-
pared with resection and adjuvant external radiation therapy
(25 months; 95% CI, 12–67), resection and neoadjuvant
external radiation therapy (19 months; 95% CI, 8–37), or
resection alone (19 months; 95% CI, 7–27; P ¼ .0001;
Figure 1, B).
In the Surg group, 5 of the 63 resected patients had pos-
itive margins. All had T3 tumors: 3 at a lung margin and 2 in
the chest wall. Three of these 5 patients received postoper-
ative radiation therapy and subsequently died of lung cancer
at 12, 19, and 28 months. One of these was an operative
death; also, 1 patient died of cardiovascular disease at 64
months. In the Chemo-RT group, 4 of the 47 patients under-
going resection had positive margins: 2 at the lung margin
and 2 in the peribronchial lymphatics. In 1 patient, the
mediastinal tissue also was positive for tumor. All 4 patients
received postoperative chemotherapy. The 2 patients with
tumor at the lung margin died of lung cancer at 10 and 22
months. The other 2 patients are alive at 91 and 94 months.
Of the 30 patients in the Surg group who had involvement
of the parietal pleura without chest wall involvement, 3
underwent a chest wall resection, 1 of whom had a chest
wall recurrence. Only 1 of the patients who did not have
a chest wall resection had a chest wall recurrence. In thegery c June 2011
FIGURE 1. A, Kaplan–Meier curves showing adjusted survival for patients in the Chemo-RTand Surg groups. Survival difference is significant (P¼ .000).
B, Kaplan–Meier survival curves for Chemo-RTand Surg subgroups: surgery alone (17), surgery and adjuvant external radiation therapy (19), and external
radiation therapy followed by surgery (21). Survival differences are significant (P ¼ .0001). XRT, External radiation therapy.
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involvement alone underwent chest wall resection, and no
patient in this group had a local recurrence.
Sixty-two of the 63 patients in the Surg group have died.
One patient died after a pneumonectomy, and 1 patient died
after lobectomy (operative mortality, 3.2%). Thirty-six pa-
tients died of cancer: second cancer in 2, cardiovascular dis-
ease in 6, pulmonary disease in 6, other causes in 5, and
unknown causes in 7. Sites of recurrence for 23 of the 36 pa-
tients who died of cancer are shown in Table 4, according to
the patients’ original site of invasion and treatment group.
Twenty-five of the 47 patients in the Chemo-RT group
have died. One patient died after a pneumonectomy (oper-
ative mortality, 2.1%). Nine patients died of lung cancer,
5 patients died of pulmonary disease, 2 patients died of
a second cancer, 2 patients died of cardiovascular disease,
3 patients died of other causes, and 3 patients died of un-
known causes. Sites of recurrence in the 9 patients who
died of lung cancer are shown in Table 4.TABLE 4. Recurrences by original sites of invasion
Site of
metastases*
Chemo-RT
N ¼ 9
No. o
recurre
Parietal
pleura
Chest
wall
Mediastinal
fat Diaphragm
<2 cm
carina
Pulmonary
artery/atrium
Lung 1 1 2 – – – 4
Chest wall – – – – – – –
Mediastinum – – – – – – –
Brain 1 – – 1 1 1 4
Other distant
sites
3 2 – – – 3 8
*Within the Chemo-RT group, sites of recurrencewere noted in all 9 patients who died of ca
died of cancer.
The Journal of Thoracic and CarFour patients who underwent resection after induction
chemoradiotherapy had major complications. Aspiration
developed in 1 patient, followed by pneumonia and acute
respiratory distress syndrome, and the patient died. Acute
respiratory distress syndrome developed in 2 patients, in as-
sociation with pneumonia in 1 patient and bronchopleural
fistula in 1 patient. One patient had a perioperative myocar-
dial infarction.
DISCUSSION
In 1979, when our lung cancer database was constructed,
tumors invading outside the lung were considered T3 and
T3N0M0 lung cancers were classified as stage III.7 In
1986, T3 and T4 descriptors distinguished tumors on the ba-
sis of their degree of invasiveness and associated clinical
outcomes.8 T3N0M0 tumors were now classified as stage
IIIA, and T4N0M0 tumors were classified as stage IIIB. It
was not until 1997 that T3N0M0 lung cancers were
downstaged to stage IIB.6f
nces
Surg
N ¼ 23
No. of
recurrences
Parietal
pleura
Chest
wall
Mediastinal
fat Diaphragm
<2-cm
carina
Pulmonary
artery/atrium
2 2 1 1 1 2 9
1 1 1 – – – 3
– – 1 – – 1 2
3 4 – – – – 7
3 5 – – 1 2 11
ncer. In the Surg group, sites of recurrencewere noted in only 23 of the 36 patients who
diovascular Surgery c Volume 141, Number 6 1395
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with invasive cancers as defined by the Fifth Edition of
the American Joint Commission. Patients with satellite
nodules are not included.
Our treatment of T3 and subsequently T4 NSCLC fol-
lowed our approach for treating other patients with stage
III disease. Before 1988, our treatment algorithm consisted
of induction high-dose radiation therapy. With the advent of
platinum-based chemotherapy, we began using induction
chemoradiotherapy as the treatment of choice for all stage
III lung cancers. Patients whose stage was determined
only at surgery or on the basis of pathologic examination
were treated in various ways, mostly by adjuvant radiation
or surgery alone. These patients are now treated with
adjuvant chemotherapy based on the results of the LACE
meta-analysis.9 Although T3N0M0 lung cancers were
downstaged to stage IIB in 1997, we did not alter our treat-
ment regimen for these tumors based on our positive results
with induction chemoradiotherapy at that time.
The evolution of our treatment for T3 and T4 lung
cancers, although based on our treatment protocol for pa-
tients with N2 disease, parallels the evolution of treatment
for Pancoast tumors. Several series demonstrated superior
results in terms of both resectability and outcome, with the
introduction of induction radiotherapy before surgical resec-
tion.10,11 More recently, the Southwest Oncology Group
(9416, Intergroup trial 0160) has shown the superiority of
neoadjuvant chemoradiotherapy in treating these patients,
with a complete resection rate of 94% and 5-year survival
of 54% for patients undergoing a complete resection.12
Unfortunately, our database does not discriminate be-
tween T3 tumors invading the chest wall and superior sulcus
(although, in our experience, superior sulcus tumors repre-
sented a minority of patients in this report). It is recognized
that these tumors respond to neoadjuvant treatment and
may, at least theoretically, have a better prognosis than
tumors invading the chest wall. However, our results for
patients with both peripheral and central T3N0M0 and
T4N0M0 NSCLC receiving neoadjuvant chemoradiation—
with a median survival of 90 months, and 5- and 10-year
survivals of 61% and 50%, respectively—argue for the
superiority of aggressive neoadjuvant chemoradiation
over any other treatment paradigm, demonstrating a greater
than 2-fold survival difference. Although the subgroups of
patients treated with neoadjuvant radiation, adjuvant radia-
tion, and surgery alone were small, patients receiving neo-
adjuvant chemoradiation had significantly better results
than these subgroups (P ¼ .0001; Figure 1, B). Age was
the only other independent variable affecting survival.
It is imperative that mediastinal nodes be evaluated with
CT, PET, and in most cases mediastinoscopy, because neo-
adjuvant chemoradiotherapy regimens have also been effec-
tive in treating patients with stage IIIA-N2 lung cancer.13,14
In the initial part of this series, invasive staging of the1396 The Journal of Thoracic and Cardiovascular Surmediastinum was carried out only in patients with
enlarged mediastinal lymph nodes, and complete lymph
node dissections were performed only in patients with
suspected nodal disease. As a result, only 41% of the
Surg group had an invasive staging procedure, compared
with 77% in the Chemo-RT group.
Given the relatively low negative predictive index for me-
diastinal staging by CT alone, especially for patients with
a higher T stage, it seems highly likely that some patients
in the Surg group were understaged. Most of them were
treated before PET became available and mediastinoscopy
was routine. Furthermore, 10% of those dying of their can-
cer had mediastinal recurrence (Table 4). On the other hand,
despite a negative mediastinoscopy, some patients will have
nodal disease; in those receiving neoadjuvant therapy, they
also may remain understaged. Because the patients in this
series were not randomized and staging was not uniform,
the conclusions must be verified by a prospective study
with standardized staging and resection criteria.
Perhaps the most significant problem with a study of this
nature is the long time span over which it was conducted.
Although the data were prospectively gathered, there have
been significant advances in imaging and diagnosis. Surgi-
cal techniques have changed, as well as anesthetic and post-
operative management. It is difficult to know how these
factors may have affected the results: Most of the patients
in the Surg group were treated earlier in the study, whereas
most of the patients in the Chemo-RT group were treated
only in the last 20 years. This may be important because
on univariate analysis, decade of care was a significant
predictor of mortality.
In this series, there was a disparity between the numbers
of patients with parietal pleural involvement versus chest
wall involvement in the Surg group versus the Chemo-RT
group. In the Surg group, 30 of 56 patients (53%) with pe-
ripheral T3 tumors had only parietal pleural involvement,
whereas 19 patients (34%) had chest wall involvement
(Table 3). Although just 3 of the patients with parietal
pleural involvement underwent a chest wall resection, local
recurrence developed in only 1 patient. Adjuvant or neoad-
juvant treatment may have contributed to this.
In the Chemo-RT group, only 8 of 38 patients (21%) with
peripheral T3 tumors had parietal pleural involvement, and
5 of them underwent chest wall resection; 16 of the 38 pa-
tients (42%) had chest wall involvement. It is unlikely this
disparity affected the results, because local recurrence is the
principal issue of chest wall resection for patients with only
parietal pleural involvement. On the other hand, the overall
risk of local/regional recurrence was higher in the Surg
group (14/63, 22%) than in the Chemo-RT group (4/47,
9%) (Table 4). This difference is likely even higher: Sites
of recurrence were known for only 23 of the 36 patients
who died of their cancer in the Surg group, whereas all sites
were known for the 9 patients who died of their cancer in thegery c June 2011
Daly et al General Thoracic Surgery
G
T
SChemo-RT group. This suggests that Chemo-RT affects
local/regional recurrence and survival.
CONCLUSIONS
This analysis does have several biases that canbe answered
only in a prospectivemulticenter trial. Although only age and
treatment group were independent predictors of mortality,
variables such as age, FEV1, and decade of care were signif-
icantly different between the 2 groups. During the course of
this study, there was improvement in diagnosis, staging,
and management. The resolution of CT scanners has
changed, PET imaging is now available, and invasive staging
of the mediastinal lymph nodes has become routine. As such,
it is likely that a few of these patients were understaged or
overstaged, affecting patient selection. All in all, however,
the extended length of follow-up of patients in this series
and the observed difference in survival (>2-fold) strongly
support further evaluation of this aggressive approach.
The authors thank Ellina Beletsky for the preparation of this
article.
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